Narayana Institute of Cardiac Sciences is a hospital in Bommasandra, Bangalore, India, operated by the Narayana Health group.

During the past decade, Narayana Institute of Cardiac Sciences conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 7 clinical trials were completed, i.e. on average, 116.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 5 clinical trials were completed. i.e. 250% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Narayana Institute of Cardiac Sciences" #1 sponsor was "Biocad" with 3 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "United Therapeutics" with 2 trials sponsored and "Aventyn, Inc." with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Narayana Institute of Cardiac Sciences" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "AT&T" with 1 trials as a collaborator, "BMS Hospital Trust" with 1 trials as a collaborator, "University of California" with 1 trials as a collaborator and "Zephyr Technology" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Narayana Institute of Cardiac Sciences" are "Heart Failure" (2 trials), "Pulmonary Arterial Hypertension" (2 trials), "Cardiac Decompensation" (1 trials), "Follicular Non-Hodgkin's Lymphoma" (1 trials) and "Heart Failure With Preserved Ejection Fraction" (1 trials). Many other conditions were trialed in "Narayana Institute of Cardiac Sciences" in a lesser frequency.

Most popular intervention types in "Narayana Institute of Cardiac Sciences" are "Drug" (9 trials), "Biological" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Empagliflozin" (3 trials), "Paclitaxel" (2 trials), "Adalimumab" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Narayana Institute of Cardiac Sciences" are 11 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Narayana Institute of Cardiac Sciences". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Narayana Institute of Cardiac Sciences, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Narayana Institute of Cardiac Sciences, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".